REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity and TVR

25 May 2022 14:30

RNS Number : 8077M
DeepMatter Group PLC
25 May 2022
 

 

25 May 2022

 

Issue of Shares and Total Voting Rights

 

DeepMatter Group Plc (AIM: DMTR, "Deepmatter", the "Group"), the digital chemistry data and software company, announces as a result of the subscription to Ordinary Shares in the Company by Alan Aubrey, incoming Chair, application has been made for 200,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on or around 31 May 2022.

 

Following the subscription, Alan Aubrey will be interested in 207,311,393 Ordinary Shares which represents 5.17 per cent. of the issued share capital as enlarged by the subscription. The subscription price was 0.1 pence per Ordinary Share.

 

The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 4,009,897,281 Ordinary Shares. Accordingly, the figure of 4,009,897,281 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For more information contact

 

DeepMatter Group Plc 0141 548 8156 Fraser Benson, Chief Financial Officer

Canaccord Genuity Limited (Nominated Advisor and Broker) 020 7523 8000Bobbie Hilliam

Meare Consulting 07990 858548Adrian Duffield

About DeepMatter Group plc 

 

DeepMatter's SmartChemistry™ platform enables scientists across a range of industries, including pharma, biotech, agri-science, scientific publishers and contract research organisations (CROs), to easily capture, access and exploit the vast amounts of data created in chemical reactions.

 

DeepMatter integrates its proprietary chemistry data and proprietary software to significantly improve productivity, efficiency, discovery, safety and sustainability of chemical reactions for its customers.

 

DeepMatter's SmartChemistry™ platform capitalises on the combination of its cloud technology, low cost-sensors, connectivity to laboratory hardware and high-performance computing trends such as artificial intelligence (AI).

 

Visit: www.deepmatter.io and follow @deepmattergroup

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESELFDIEESEFI
Date   Source Headline
24th Jan 20228:50 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSHolding(s) in Company
20th Jan 202212:15 pmRNSResult of General Meeting
20th Jan 20227:00 amRNSResult of Open Offer - Correction
19th Jan 202211:30 amRNSResult of Open Offer
4th Jan 20221:30 pmRNSPosting of Circular and Notice of GM
29th Dec 20214:36 pmRNSPrice Monitoring Extension
24th Dec 20217:00 amRNSPlacing, Subscription and Open Offer
17th Dec 20215:00 pmRNSBusiness Update and Financing
22nd Oct 20217:00 amRNSAppointment of new Scientific Advisory Board
21st Oct 20218:00 amRNSDigitalGlassware® platform trial with Aurigene
28th Sep 20217:00 amRNSCollaboration
22nd Sep 20217:00 amRNSHalf Year Results
14th Sep 202110:30 amRNSNotice of Half Year Results
8th Sep 20211:30 pmRNSHolding(s) in Company
18th Aug 20217:00 amRNSAdvisory Board Appointment
5th Aug 20217:00 amRNSCollaboration with the University of Cambridge
12th Jul 20217:00 amRNSAppointment of Non-Executive Director
30th Jun 20213:34 pmRNSResult of AGM
22nd Jun 20217:00 amRNSChanges to 2021 AGM Arrangements
17th Jun 20217:00 amRNSCollaboration with the University of Leeds
8th Jun 20213:16 pmRNSPosting of ARA and Updated Notice of AGM
1st Jun 20217:00 amRNSFinal Results
24th May 20217:00 amRNSNotice of Results and Investor Presentation
6th May 20213:43 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSCollaboration with the University of Nottingham
11th Mar 20217:00 amRNSCo-distribution agreement with Elemental Machines
9th Mar 20217:00 amRNSDirectorate Change
20th Jan 20217:00 amRNSAgreement with Merck's Life Sciences business
19th Jan 20217:00 amRNSHolding(s) in Company
8th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Dec 202010:30 amRNSGrant of PDMR Options
17th Dec 20207:00 amRNSMulti-year contract with Thieme Chemistry
26th Oct 202011:05 amRNSSecond Price Monitoring Extn
26th Oct 202011:00 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSIssue of Shares and Total Voting Rights
19th Oct 20207:00 amRNSDirectorate Changes
16th Oct 20207:00 amRNSStrong adoption of ICSYNTH
2nd Oct 20202:05 pmRNSSecond Price Monitoring Extn
2nd Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 20208:00 amRNSGrant of Options
29th Sep 20207:00 amRNSHolding(s) in Company
23rd Sep 20201:40 pmRNSHolding(s) in Company
22nd Sep 20204:29 pmRNSHolding(s) in Company
22nd Sep 20204:00 pmRNSHolding(s) in Company
22nd Sep 202010:32 amRNSHolding(s) in Company
15th Sep 20208:08 amRNSIssue of Shares and Total Voting Rights
10th Sep 20207:00 amRNSHalf-year Report
4th Sep 20208:26 amRNSHolding(s) in Company
3rd Sep 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.